Tiny study probes COVID antibodies in cystic fibrosis patients

NCT ID NCT05074680

Completed Knowledge-focused Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study followed 5 people with cystic fibrosis over two years to track COVID-19 antibodies from infection or vaccination. Researchers collected blood samples every six months to see how antibodies develop and last. The goal was to understand if people with CF have different immune responses to COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help explain why some people with cystic fibrosis may have milder COVID-19 and guide better care.
What could go wrong: This is a very small observational study (5 participants) that only measures antibodies, not clinical outcomes. Results may not apply to all people with cystic fibrosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

University Children's hospital Bern

Bern, 3010, Switzerland
University Children's hospital, Zürich

Zurich, 8032, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.